



APR Applied Pharma Research s.a. ("APR") today announced that HBM Partners ("HBM") has acquired a minority stake in APR.

HBM Partners Invests in APR Applied Pharma Research SA

Balerna and Zug (Switzerland), March 25th, 2015

HBM BioCapital II LP, advised by HBM Partners ("HBM"), one of the leading Swiss Private Equity Investors and global leader in healthcare-focused investments, has acquired a minority stake in the Swiss company APR Applied Pharma Research SA ("APR") for an undisclosed amount. The fund's advisor, Alexander Asam, will become a member of the Board of Directors of APR.

"We have followed the progress of APR for quite some time and are pleased to invest in APR. This investment underlines our strategy to invest in attractive, growing and internationally oriented firms. APR with its proven track record in formulation and development provides growth opportunities in various segments of the Healthcare industry" said Dr. Alexander Asam of HBM.

"We are pleased and honored to welcome HBM among our Shareholders", said Paolo Galfetti, CEO and co-founder of APR, "over the last few years we have nicely progressed in transitioning APR from an entirely family owned company into a private, fast growing and revenue generating corporation with an exceptional track record in developing and licensing-out patient-centric, science driven and patent protected Healthcare products on a global basis. We are excited to be part of HBM's portfolio companies and we are confident that HBM, together with our other institutional investor Bright Technology Fund, will be able to bring additional value to APR. Finally, we are also pleased about the opportunity to work with Alexander Asam who will bring to APR his extensive expertise and network in the pharmaceutical industry."

As part of the transaction, Valentina Reiner, co-founder of APR, will resign from the board of APR while maintaining her management role within the company: we are all grateful to Valentina for all the efforts, dedication and value she offered to APR over her tenure.

About APR Applied Pharma Research s.a.

APR is a Swiss, independent developer of science driven, patent protected Healthcare products. The Company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in selected therapeutical areas on a global basis. In particular, APR is currently focused on 2 (two) areas: (i) internally developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development. APR has entered into licensing and partnership



agreements with pharmaceutical companies in over 70 countries with international sales on a worldwide basis. For press releases and other company information visit: www.apr.ch

About HBM Partners AG

HBM Partners is among the global leaders in healthcare-focused investing with over USD 1 bn under management. HBM focuses on development stage, growth and buy-out financings of private companies as well as investments in public companies. HBM Partners advises HBM Healthcare Investments AG, HBM BioCapital and further specialized private-equity and public-equity funds. HBM has a complementary team of experienced professionals to source, analyze, execute and exit investments in the pharma/biotech, medical devices and diagnostics industries. HBM Partners has been an active contributor to value creation in its portfolio companies, generating over 40 trade sales and IPOs since inception. More information can be found at www.hbmpartners.com

Contacts:

HBM Partners AG,

Dr. Alexander Asam

T: +41 43 888 71 08 or email to alexander.asam@hbmpartners.com

APR Applied Pharma Research s.a.,

Paolo Galfetti; CEO

T: +41 91 6957020 or email to paolo.galfetti@apr.ch